Literature DB >> 16896109

Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.

Demetrius M Maraganore1, Mariza de Andrade, Alexis Elbaz, Matthew J Farrer, John P Ioannidis, Rejko Krüger, Walter A Rocca, Nicole K Schneider, Timothy G Lesnick, Sarah J Lincoln, Mary M Hulihan, Jan O Aasly, Tetsuo Ashizawa, Marie-Christine Chartier-Harlin, Harvey Checkoway, Carlo Ferrarese, Georgios Hadjigeorgiou, Nobutaka Hattori, Hideshi Kawakami, Jean-Charles Lambert, Timothy Lynch, George D Mellick, Spiridon Papapetropoulos, Abbas Parsian, Aldo Quattrone, Olaf Riess, Eng-King Tan, Christine Van Broeckhoven.   

Abstract

CONTEXT: Identification and replication of susceptibility genes for Parkinson disease at the population level have been hampered by small studies with potential biases. Alpha-synuclein (SNCA) has been one of the most promising susceptibility genes, but large-scale studies have been lacking.
OBJECTIVE: To determine whether allele-length variability in the dinucleotide repeat sequence (REP1) of the SNCA gene promoter is associated with Parkinson disease susceptibility, whether SNCA promoter haplotypes are associated with Parkinson disease, and whether REP1 variability modifies age at onset. DESIGN, SETTING, AND PARTICIPANTS: We performed a collaborative analysis of individual-level data on SNCA REP1 and flanking markers in patients with Parkinson disease and controls. Study site recruitment, data collection, and analyses were performed between April 5, 2004, and December 31, 2005. Eighteen participating sites of a global genetics consortium provided clinical data. Genotyping was performed for SNCA REP1, -770, and -116 markers at individual sites; however, each site also provided 20 DNA samples for regenotyping centrally. MAIN OUTCOME MEASURES: Measures included estimations of Hardy-Weinberg equilibrium in controls; a test of heterogeneity; analyses for association of single variants or haplotypes; and survival analyses for age at onset.
RESULTS: Of the 18 sites, 11 met stringent criteria for concordance with Hardy-Weinberg equilibrium and low genotyping error rate. These 11 sites provided complete data for 2692 cases and 2652 controls. There was no heterogeneity across studies (P>.60). The SNCA REP1 alleles differed in frequency for cases and controls (P<.001). Genotypes defined by the 263 base-pair allele were associated with Parkinson disease (odds ratio, 1.43; 95% confidence interval, 1.22-1.69; P<.001 for trend). Multilocus haplotypes differed in frequency for cases and controls (global score statistic, P<.001). Two-loci haplotypes were associated with Parkinson disease only when they included REP1 as one of the loci. However, genotypes defined by REP1 alleles did not modify age at onset (P = .55).
CONCLUSION: This large-scale collaborative analysis demonstrates that SNCA REP1 allele-length variability is associated with an increased risk of Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896109     DOI: 10.1001/jama.296.6.661

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  215 in total

1.  Age at onset in LRRK2-associated PD is modified by SNCA variants.

Authors:  Teresa Botta-Orfila; Mario Ezquerra; Pau Pastor; Rubén Fernández-Santiago; Claustre Pont-Sunyer; Yaroslau Compta; Oswaldo Lorenzo-Betancor; Lluis Samaranch; Maria José Martí; Francesc Valldeoriola; Matilde Calopa; Manel Fernández; Miquel Aguilar; Oriol de Fabregas; Jorge Hernández-Vara; Eduard Tolosa
Journal:  J Mol Neurosci       Date:  2012-06-06       Impact factor: 3.444

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

Review 3.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

4.  Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.

Authors:  Ahmad Jowaed; Ina Schmitt; Oliver Kaut; Ullrich Wüllner
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

5.  SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

Authors:  Ignacio F Mata; Min Shi; Pinky Agarwal; Kathryn A Chung; Karen L Edwards; Stewart A Factor; Douglas R Galasko; Carmen Ginghina; Alida Griffith; Donald S Higgins; Denise M Kay; Hojoong Kim; James B Leverenz; Joseph F Quinn; John W Roberts; Ali Samii; Katherine W Snapinn; Debby W Tsuang; Dora Yearout; Jing Zhang; Haydeh Payami; Cyrus P Zabetian
Journal:  Arch Neurol       Date:  2010-11

6.  Synuclein expression in the lizard Anolis carolinensis.

Authors:  Mattia Toni; Carla Cioni; Federica De Angelis; Maria Carmela Bonaccorsi di Patti
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2016-07-08       Impact factor: 1.836

Review 7.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

8.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 10.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.